Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Bucharest Oncology Institute, Bucharest, Romania

Survival: 9.6 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Romania
City/State/Province: Bucharest
Hospital: Bucharest Oncology Institute
Journal: Link
Date: 8/2007

Patients: This phase II trial involved 102 patients with stage III and IV non-small cell lung cancer. The patients were divided into two groups: one group had a mean age of 59, and the other, 56 years. In both groups, the majority were men.

Treatment: One group received the chemotherapy drugs gemcitabine and vinorelbine followed by gemcitabine and ifosfamide The other group received gemcitabine and cisplatin.

Toxicity: Toxicity was similar between the two treatment groups. Grade 3/4 leukopenia, granulocytopenia, anemia, thrombocytopenia, and hemorrhage were reported in 0-12.2% of patients. Non-hematological toxicities occurred in 0-14% of patients.

Results: The overall survival was 9.7 months in the gemcitabine-cisplatin treated patients, and 6.5 months in the gemcitabine-vinorelbine-ifosfamide treated patients. These survival times were not statistically different.

Support: Eli Lilly and Company provided research funds and was involved in the design and analysis of the study data. Eli Lilly developed and markets gemcitabine as Gemzar®.

Correspondence: Dr. Alexandru Grigorescu

E-mail to a Friend Email Physician More Information